SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totaling 21,800 shares, a decline of 34.3% from the September 30th total of 33,200 shares. Based on an average daily volume of 87,500 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 87,500 shares, the short-interest ratio is currently 0.2 days.Get SOPHiA GENETICS alerts:Hedge Funds Weigh In On SOPHiA GENETICSA number of institutional investors have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock valued at $25,341,000 after purchasing an additional 5,432,871 shares during the period. Akre Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock valued at $11,529,000 after buying an additional 1,481,636 shares in the last quarter. Archon Capital Management LLC purchased a new position in shares of SOPHiA GENETICS during the 2nd quarter valued at about $997,000. Ensign Peak Advisors Inc bought a new position in shares of SOPHiA GENETICS during the 2nd quarter valued at approximately $775,000. Finally, Rathbones Group PLC purchased a new stake in SOPHiA GENETICS in the 2nd quarter worth approximately $504,000. 31.59% of the stock is owned by institutional investors. Wall Street Analyst Weigh InSeveral brokerages recently issued reports on SOPH. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Wednesday, October 8th. Wall Street Zen raised SOPHiA GENETICS to a "hold" rating in a report on Saturday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $8.00.Check Out Our Latest Report on SOPHSOPHiA GENETICS Stock PerformanceShares of SOPH traded down $0.19 on Friday, reaching $5.00. The company's stock had a trading volume of 157,207 shares, compared to its average volume of 139,344. The stock's 50 day simple moving average is $3.89 and its two-hundred day simple moving average is $3.41. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.39 and a quick ratio of 3.21. The stock has a market capitalization of $337.90 million, a P/E ratio of -11.36 and a beta of 1.10. SOPHiA GENETICS has a 12-month low of $2.58 and a 12-month high of $5.30. SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.58. The business had revenue of $18.32 million for the quarter, compared to the consensus estimate of $17.49 million. SOPHiA GENETICS had a negative net margin of 40.99% and a negative return on equity of 30.69%. SOPHiA GENETICS has set its FY 2025 guidance at EPS. Research analysts forecast that SOPHiA GENETICS will post -0.96 earnings per share for the current fiscal year. SOPHiA GENETICS Company Profile (Get Free Report)SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.See AlsoFive stocks we like better than SOPHiA GENETICSWhat is a Low P/E Ratio and What Does it Tell Investors?Is Lemonade Stock Set for a Big Squeeze After Earnings?3 Grocery Stocks That Can Help Take a Bite Out of Inflation Caterpillar Stock Could Top $650 by Year’s End3 REITs to Buy and Hold for the Long TermServiceNow’s 5-for-1 Split Is a Signal for Investors to BuyThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in SOPHiA GENETICS Right Now?Before you consider SOPHiA GENETICS, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SOPHiA GENETICS wasn't on the list.While SOPHiA GENETICS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here